

Silvia G Priori

List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/898219/publications.pdf](https://exaly.com/author-pdf/898219/publications.pdf)

Version: 2025-02-01

361

PR articles

66,466

PR citations

479

113

PR h-index

373

254

g-index

415

documents

81519

doc citations

518

123

h-index

48469

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Value of 3D echocardiography in the diagnosis of arrhythmogenic right ventricular cardiomyopathy. <i>European Heart Journal Cardiovascular Imaging</i> , 2023, 24, 664-677.	1.4	9
2	Characterization of Skeletal Muscle Biopsy and Derived Myoblasts in a Patient Carrying Arg14del Mutation in Phospholamban Gene. <i>Cells</i> , 2023, 12, 1405.	4.8	5
3	Desmoplakin cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy: two distinct forms of cardiomyopathy?. <i>Minerva Cardiology and Angiology</i> , 2022, 70, .	1.2	4
4	Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk). <i>Europace</i> , 2022, 24, 614-619.	2.1	49
5	Cardiac ryanodine receptors: is a severe loss-of-function not so severe after all?. <i>Europace</i> , 2022, 24, 494-496.	2.1	2
6	La estimulación eléctrica programada para la predicción del riesgo en pacientes con síndrome de Brugada: ¿tiempo de cierre?. <i>Revista Española De Cardiología</i> , 2022, , .	1.1	0
7	Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk): comment "Authors' reply. <i>Europace</i> , 2022, 24, 698-699.	2.1	8
8	Rare Variation in Drug Metabolism and Long QT Genes and the Genetic Susceptibility to Acquired Long QT Syndrome. <i>Circulation Genomic and Precision Medicine</i> , 2022, 15, .	3.3	9
9	Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β -Blockers. <i>JAMA Cardiology</i> , 2022, 7, 504.	10.4	63
10	Programmed electrophysiological stimulation for risk prediction in patients with Brugada syndrome: closing time?. <i>Revista Española De Cardiología (English Ed)</i> , 2022, , .	0.5	0
11	Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator. <i>European Heart Journal</i> , 2022, 43, 3041-3052.	2.3	69
12	TRPM4 inhibition by meclofenamate suppresses Ca ²⁺ -dependent triggered arrhythmias. <i>European Heart Journal</i> , 2022, 43, 4195-4207.	2.3	28
13	Left Ventricular Myocardial Work in Patients with Severe Aortic Stenosis. <i>Journal of the American Society of Echocardiography</i> , 2021, 34, 257-266.	3.5	84
14	Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls. <i>Genetics in Medicine</i> , 2021, 23, 47-58.	4.3	89
15	Peptide-Based Targeting of the L-Type Calcium Channel Corrects the Loss-of-Function Phenotype of Two Novel Mutations of the CACNA1 Gene Associated With Brugada Syndrome. <i>Frontiers in Physiology</i> , 2021, 11, .	2.9	14
16	Evolving determinants of carotid atherosclerosis vulnerability in asymptomatic patients from the MAGNETIC observational study. <i>Scientific Reports</i> , 2021, 11, .	3.5	5
17	Cardiac ryanodine receptor calcium release deficiency syndrome. <i>Science Translational Medicine</i> , 2021, 13, .	12.7	100
18	Identification of loss-of-function RyR2 mutations associated with idiopathic ventricular fibrillation and sudden death. <i>Bioscience Reports</i> , 2021, 41, .	4.0	36

#	ARTICLE	IF	PR CITATIONS
19	Precision Medicine in Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2592-2612.	2.4	60
20	ESC CONGRESS 2020"the digital experience: expanding the reach of the society. <i>European Heart Journal</i> , 2021, 42, 2812-2813.	2.3	1
21	Management of Congenital Long-QT Syndrome: Commentary From the Experts. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, .	7.4	16
22	Genotype-Phenotype Correlation of <i>SCN5A</i> Genotype in Patients With Brugada Syndrome and Arrhythmic Events: Insights From the SABRUS in 392 Proband. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, .	3.3	15
23	Digital transformation of major scientific meetings induced by the COVID-19 pandemic: insights from the ESC 2020 annual congress. <i>European Heart Journal Digital Health</i> , 2021, 2, 704-712.	2.3	4
24	Additional diagnostic value of cardiac magnetic resonance feature tracking in patients with biopsy-proven arrhythmogenic cardiomyopathy. <i>International Journal of Cardiology</i> , 2021, 339, 203-210.	2.3	11
25	Prevalence and clinical implications of cardiac involvement in individuals with paucisymptomatic SARS-CoV-2 infection. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0
26	Differential pharmacological modulation of arrhythmic phenotype in catecholaminergic polymorphic ventricular tachycardia: not all betablockers are the same. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0
27	Inherited conditions of arrhythmia: translating disease mechanisms to patient management. <i>Cardiovascular Research</i> , 2020, 116, 1539-1541.	5.7	7
28	An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of <i>CASQ2</i> -Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Circulation</i> , 2020, 142, 932-947.	25.2	75
29	Cell identity and nucleo-mitochondrial genetic context modulate OXPHOS performance and determine somatic heteroplasmy dynamics. <i>Science Advances</i> , 2020, 6, .	11.0	43
30	Stabilizer Cell Gene Therapy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, .	7.4	18
31	ESC Core Curriculum for the Cardiologist. <i>European Heart Journal</i> , 2020, 41, 3605-3692.	2.3	60
32	A Network of Macrophages Supports Mitochondrial Homeostasis in the Heart. <i>Cell</i> , 2020, 183, 94-109.e23.	34.1	658
33	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. <i>Circulation</i> , 2020, 142, 324-338.	25.2	129
34	Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy. <i>Circulation</i> , 2020, 141, 1872-1884.	25.2	414
35	Tetrodotoxin-sensitive Neuronal ⁺ Na ⁺ Channels: A Novel and Druggable Target for Prevention of Atrial Fibrillation. <i>Journal of the American Heart Association</i> . 2020. 9, .	4.3	16
36	Warning: not all carriers of pathogenic mutations in desmosomal genes should follow the same medical advices!. <i>Cardiovascular Research</i> , 2020, 116, 1085-1088.	5.7	1

#	ARTICLE	IF	PR CITATIONS
37	An International Multicenter Evaluation of Type 5 Long QT Syndrome. <i>Circulation</i> , 2020, 141, 429-439.	25.2	54
38	Continued misuse of orphan drug legislation: a life-threatening risk for mexiletine. <i>European Heart Journal</i> , 2020, 41, 614-617.	2.3	20
39	Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1772-1784.	2.4	65
40	Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. <i>European Heart Journal</i> , 2020, 41, 2083-2088.	2.3	788
41	Ranolazine as an Alternative Therapy to Flecainide for SCN5A V411M Long QT Syndrome Type 3 Patients. <i>Frontiers in Pharmacology</i> , 2020, 11, .	4.0	10
42	Enhancement of Cardiac Store Operated Calcium Entry (SOCE) within Novel Intercalated Disk Microdomains in Arrhythmic Disease. <i>Scientific Reports</i> , 2019, 9, .	3.5	37
43	Ethnic differences in patients with Brugada syndrome and arrhythmic events: New insights from Survey on Arrhythmic Events in Brugada Syndrome. <i>Heart Rhythm</i> , 2019, 16, 1468-1474.	2.8	30
44	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. <i>Heart Rhythm</i> , 2019, 16, e373-e407.	2.8	173
45	Severe Cardiac Dysfunction and Death Caused by Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Are Improved by Inhibition of Glycogen Synthase Kinase-3 β . <i>Circulation</i> , 2019, 140, 1188-1204.	25.2	87
46	Supervised methods to extract clinical events from cardiology reports in Italian. <i>Journal of Biomedical Informatics</i> , 2019, 95, 103219.	3.8	18
47	Dilated cardiomyopathy. <i>Nature Reviews Disease Primers</i> , 2019, 5, .	50.7	571
48	Efficacy and Limitations of Quinidine in Patients With Brugada Syndrome. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, .	7.4	26
49	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. <i>Heart Rhythm</i> , 2019, 16, e301-e372.	2.8	689
50	Characterization and Management of Arrhythmic Events in Young Patients With Brugada Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1756-1765.	2.4	65
51	What a Congress!. <i>European Heart Journal</i> , 2019, 40, 3507-3509.	2.3	0
52	Time-to-first appropriate shock in patients implanted prophylactically with an implantable cardioverter-defibrillator: data from the Survey on Arrhythmic Events in BRUGADA Syndrome (SABRUS). <i>Europace</i> , 2019, 21, 796-802.	2.1	20
53	Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation. <i>Circulation Research</i> , 2019, 124, 539-552.	12.5	58
54	International Triadin Knockout Syndrome Registry. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, .	3.3	45

#	ARTICLE	IF	PR CITATIONS
55	Genetic risk stratification in cardiac arrhythmias. <i>Current Opinion in Cardiology</i> , 2018, 33, 298-303.	1.7	9
56	Interplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT Syndrome. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1663-1671.	2.4	195
57	Fever-related arrhythmic events in the multicenter Survey on Arrhythmic Events in Brugada Syndrome. <i>Heart Rhythm</i> , 2018, 15, 1394-1401.	2.8	83
58	Profile of patients with Brugada syndrome presenting with their first documented arrhythmic event: Data from the Survey on Arrhythmic Events in BRUGADA Syndrome (SABRUS). <i>Heart Rhythm</i> , 2018, 15, 716-724.	2.8	73
59	Information extraction from Italian medical reports: An ontology-driven approach. <i>International Journal of Medical Informatics</i> , 2018, 111, 140-148.	3.4	19
60	Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Journal of the American Heart Association</i> , 2018, 7, .	4.3	39
61	CardioVAI: An automatic implementation of ACMG-AMP variant interpretation guidelines in the diagnosis of cardiovascular diseases. <i>Human Mutation</i> , 2018, 39, 1835-1846.	3.9	43
62	Cardiac Magnetic Resonance in Stable Coronary Artery Disease: Added Prognostic Value to Conventional Risk Profiling. <i>BioMed Research International</i> , 2018, 2018, 1-10.	2.5	10
63	J-Wave Syndromes. <i>Cardiac Electrophysiology Clinics</i> , 2018, 10, 355-369.	1.1	14
64	Gender differences in patients with Brugada syndrome and arrhythmic events: Data from a survey on arrhythmic events in 678 patients. <i>Heart Rhythm</i> , 2018, 15, 1457-1465.	2.8	78
65	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. <i>Europace</i> , 2017, , euw243.	2.1	89
66	The Phenotypic Spectrum of a Mutation Hotspot Responsible for the Short QT Syndrome. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 727-743.	3.6	70
67	Allele-Specific Silencing of Mutant mRNA Rescues Ultrastructural and Arrhythmic Phenotype in Mice Carriers of the R4496C Mutation in the Ryanodine Receptor Gene () Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 262 Td (12.5 94 <i>R		
68	Diagnosis of Long QT Syndrome: Time to Stand Up!. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 898-900.	0.5	1
69	The new kids on the block of arrhythmogenic disorders: Short QT syndrome and early repolarization. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 1226-1236.	2.1	32
70	Genetic causes of sudden cardiac death in the young. <i>Current Opinion in Cardiology</i> , 2017, 32, 253-261.	1.7	10
71	Diagnóstico del síndrome de QT largo: valor del ortostatismo. <i>Revista Espanola De Cardiologia</i> , 2017, 70, 898-900.	1.1	1
72	Genetic causes of sudden cardiac death in children: inherited arrhythmogenic diseases. <i>Current Opinion in Pediatrics</i> , 2017, 29, 552-559.	2.4	12

#	ARTICLE	IF	PR CITATIONS
73	Hydroquinidine Prevents Life-Threatening Arrhythmic Events in Patients With Short QT Syndrome. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3010-3015.	2.4	88
74	Suppression of Arrhythmia by Enhancing Mitochondrial Ca ²⁺ Uptake in Catecholaminergic Ventricular Tachycardia Models. <i>JACC Basic To Translational Science</i> , 2017, 2, 737-747.	3.4	48
75	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 41-69.	2.1	210
76	Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent?. <i>Heart Rhythm</i> , 2017, 14, e41-e44.	2.8	110
77	Age of First Arrhythmic Event in Brugada Syndrome. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	7.4	74
78	Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. <i>JAMA Cardiology</i> , 2017, 2, 759.	10.4	164
79	Clinical Presentation and Outcome of Brugada Syndrome Diagnosed With the New 2013 Criteria. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 937-943.	2.1	22
80	Electrocardiographic features of sudden unexpected death in epilepsy. <i>Epilepsia</i> , 2016, 57, .	4.6	34
81	Is There a Role for Genetics in the Prevention of Sudden Cardiac Death?. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 1124-1132.	2.1	13
82	Arrhythmogenic Right Ventricular Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2540-2550.	2.4	172
83	Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. <i>Revista Espanola De Cardiología</i> , 2016, 69, 1167.e1-1167.e85.	1.1	119
84	Neuronal Na ⁺ Channels Are Integral Components of Pro-Arrhythmic Na ⁺ /Ca ²⁺ Signaling Nanodomain That Promotes Cardiac Arrhythmias During β^2 -Adrenergic Stimulation. <i>JACC Basic To Translational Science</i> , 2016, 1, 251-266.	3.4	37
85	Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia. <i>Cell Death and Disease</i> , 2016, 7, e2393-e2393.	8.7	58
86	Role of the JP45-Calsequestrin Complex on Calcium Entry in Slow Twitch Skeletal Muscles. <i>Journal of Biological Chemistry</i> , 2016, 291, 14555-14565.	2.2	13
87	Programmed Ventricular Stimulation for Risk Stratification in the Brugada Syndrome. <i>Circulation</i> , 2016, 133, 622-630.	25.2	237
88	Programmed ventricular stimulation early after myocardial infarction: authors' reply. <i>Europace</i> , 2016, 18, 789.2-790.	2.1	0
89	Guía ESC 2015 sobre el tratamiento de pacientes con arritmias ventriculares y prevención de la muerte súbita cardiaca. <i>Revista Espanola De Cardiología</i> , 2016, 69, 176.e1-176.e77.	1.1	23
90	2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. <i>Revista Espanola De Cardiología (English Ed)</i> , 2016, 69, 176.	0.5	58

#	ARTICLE	IF	PR CITATIONS
91	Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1053-1058.	2.4	235
92	Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Heart Lung and Circulation</i> , 2016, 25, 777-783.	1.0	46
93	R4496C RyR2 mutation impairs atrial and ventricular contractility. <i>Journal of General Physiology</i> , 2016, 147, 39-52.	2.4	23
94	Linee guida ESC 2015 per il trattamento dei pazienti con aritmie ventricolari e la prevenzione della morte cardiaca improvvisa. Task Force per il Trattamento dei Pazienti con Aritmie Ventricolari e la Prevenzione della Morte Cardiaca Improvvisa della Società Europea di Cardiologia (ESC). <i>Giornale Italiano Di Cardiologia</i> , 2016, 17, .	0.0	32
95	Genetics of Sudden Cardiac Death. <i>Circulation Research</i> , 2015, 116, 1919-1936.	12.5	257
96	From decision to shared-decision: Introducing patients' preferences into clinical decision analysis. <i>Artificial Intelligence in Medicine</i> , 2015, 65, 19-28.	5.9	28
97	Use of Whole Exome Sequencing for the Identification of <i>hERG</i> -Based Arrhythmia Mechanism and Therapy. <i>Journal of the American Heart Association</i> , 2015, 4, .	4.3	16
98	Neuronal Na ⁺ channel blockade suppresses arrhythmogenic diastolic Ca ²⁺ release. <i>Cardiovascular Research</i> , 2015, 106, 143-152.	5.7	44
99	Unusual retrospective prenatal findings in a male newborn with Timothy syndrome type 1. <i>European Journal of Medical Genetics</i> , 2015, 58, 332-335.	1.6	17
100	Genetic modulators of the phenotype in the long QT syndrome: state of the art and clinical impact. <i>Current Opinion in Genetics and Development</i> , 2015, 33, 17-24.	3.2	22
101	Gene therapy to treat cardiac arrhythmias. <i>Nature Reviews Cardiology</i> , 2015, 12, 531-546.	37.5	52
102	Genotype-dependent differences in age of manifestation and arrhythmia complications in short QT syndrome. <i>International Journal of Cardiology</i> , 2015, 190, 393-402.	2.3	78
103	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. <i>Europace</i> , 2015, , euv319.	2.1	659
104	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. <i>European Heart Journal</i> , 2015, 36, 2793-2867.	2.3	3,494
105	<i>hERG</i> Blockade by Iboga Alkaloids. <i>Cardiovascular Toxicology</i> , 2015, 16, 14-22.	3.6	34
106	Genetically engineered SCN5A mutant pig hearts exhibit conduction defects and arrhythmias. <i>Journal of Clinical Investigation</i> , 2015, 125, 403-412.	10.7	104
107	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. <i>Kardiologia Polska</i> , 2015, 73, 795-900.	0.6	45
108	The usual suspects in sudden cardiac death of the young: a focus on inherited arrhythmogenic diseases. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 499-519.	1.9	37

#	ARTICLE	IF	PR CITATIONS
109	The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. <i>European Heart Journal</i> , 2014, 35, 3250-3257.	2.3	88
110	Genetic testing to predict sudden cardiac death: current perspectives and future goals. <i>Indian Heart Journal</i> , 2014, 66, S58-S60.	0.6	16
111	Genetically induced dysfunctions of Kir2.1 channels: implications for short QT3 syndrome and autism-epilepsy phenotype. <i>Human Molecular Genetics</i> , 2014, 23, 4875-4886.	3.0	76
112	Subclinical Abnormalities in Sarcoplasmic Reticulum Ca ²⁺ Release Promote Eccentric Myocardial Remodeling and Pump Failure Death in Response to Pressure Overload. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1569-1579.	2.4	50
113	Missense Mutations in Plakophilin-2 Cause Sodium Current Deficit and Associate With a Brugada Syndrome Phenotype. <i>Circulation</i> , 2014, 129, 1092-1103.	25.2	324
114	Congenital Long QT Syndrome Type 3. <i>Cardiac Electrophysiology Clinics</i> , 2014, 6, 705-713.	1.1	3
115	Sodium Current Disorders. <i>Cardiac Electrophysiology Clinics</i> , 2014, 6, 825-833.	1.1	0
116	Single Delivery of an Adeno-Associated Viral Construct to Transfer the <i>CASQ2</i> Gene to Knock-In Mice Affected by Catecholaminergic Polymorphic Ventricular Tachycardia Is Able to Cure the Disease From Birth to Advanced Age. <i>Circulation</i> , 2014, 129, 2673-2681.	25.2	111
117	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2014, 35, 2733-2779.	2.3	4,009
118	Epidemiology of sudden cardiac death in Cameroon: Rationale and design of the Douala-SUD survey. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 433-442.	1.6	11
119	Novel Insight Into the Natural History of Short QT Syndrome. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1300-1308.	2.4	216
120	Rationale and design of the Pan-African Sudden Cardiac Death survey: the Pan-African SCD study : cardiovascular topic. <i>Cardiovascular Journal of Africa</i> , 2014, 25, 176-184.	0.6	15
121	Quando l'ECG basale suggerisce il rischio di morte improvvisa. <i>Giornale Italiano Di Cardiologia</i> , 2014, 15, .	0.0	1
122	Executive Summary: HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. <i>Heart Rhythm</i> , 2013, 10, e85-e108.	2.8	180
123	HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. <i>Heart Rhythm</i> , 2013, 10, 1932-1963.	2.8	1,783
124	<i>KCNJ2</i> mutation in short QT syndrome 3 results in atrial fibrillation and ventricular proarrhythmia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 4291-4296.	7.6	146
125	Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. <i>Europace</i> , 2013, 15, 1389-1406.	2.1	528
126	Decreased RyR2 refractoriness determines myocardial synchronization of aberrant Ca ²⁺ release in a genetic model of arrhythmia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 10312-10317.	7.6	56

#	ARTICLE	IF	PR CITATIONS
127	Abnormal Propagation of Calcium Waves and Ultrastructural Remodeling in Recessive Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Circulation Research</i> , 2013, 113, 142-152.	12.5	46
128	Induced pluripotent stem cell-derived cardiomyocytes in studies of inherited arrhythmias. <i>Journal of Clinical Investigation</i> , 2013, 123, 84-91.	10.7	58
129	Torsade de Pointes. <i>Drugs</i> , 2012, 47, 51-65.	11.8	45
130	A Clinical Approach to Inherited Arrhythmias. <i>Circulation: Cardiovascular Genetics</i> , 2012, 5, 581-590.	3.9	28
131	Sudden Cardiac Death and Genetic Ion Channelopathies. <i>Circulation</i> , 2012, 125, 2027-2034.	25.2	143
132	Genetics of ion-channel disorders. <i>Current Opinion in Cardiology</i> , 2012, 27, 242-252.	1.7	37
133	Paradoxical Effect of Increased Diastolic Ca ²⁺ Release and Decreased Sinoatrial Node Activity in a Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Circulation</i> , 2012, 126, 392-401.	25.2	83
134	The European CRT Survey: 1 year (9-15 months) follow-up results. <i>European Journal of Heart Failure</i> , 2012, 14, 61-73.	7.8	91
135	Molecular Autopsy for Sudden Unexplained Death? Time to Discuss Pros and Cons. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 1099-1102.	2.1	14
136	Genetics and Arrhythmias: Diagnostic and Prognostic Applications. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 278-286.	0.5	9
137	Genética y arritmias: aplicaciones diagnósticas y pronósticas. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 278-286.	1.1	36
138	An ICT infrastructure to integrate clinical and molecular data in oncology research. <i>BMC Bioinformatics</i> , 2012, 13, .	3.0	26
139	Late gadolinium enhancement by cardiovascular magnetic resonance is complementary to left ventricle ejection fraction in predicting prognosis of patients with stable coronary artery disease. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2012, 14, 28.	4.5	35
140	Inherited calcium channelopathies in the pathophysiology of arrhythmias. <i>Nature Reviews Cardiology</i> , 2012, 9, 561-575.	37.5	172
141	Risk Stratification in Brugada Syndrome. <i>Journal of the American College of Cardiology</i> , 2012, 59, 37-45.	2.4	560
142	Flecainide and Antiarrhythmic Effects in a Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Trends in Cardiovascular Medicine</i> , 2012, 22, 35-39.	7.5	11
143	Risk Stratification in the Long QT Syndrome. <i>Cardiac Electrophysiology Clinics</i> , 2012, 4, 53-60.	1.1	26
144	How to Interpret Results of Genetic Testing and Counsel Families. <i>Cardiac Electrophysiology Clinics</i> , 2012, 4, 97-101.	1.1	0

#	ARTICLE	IF	PR CITATIONS
145	ONCO-i2b2: improve patients selection through CBR techniques with heterogeneous distance functions. EMBnet Journal, 2012, 18, 145.	0.6	0
146	The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades. European Journal of Heart Failure, 2011, 13, 974-983.	7.8	103
147	Role of calmodulin kinase in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm, 2011, 8, 1601-1605.	2.8	7
148	Risk for Life-Threatening Cardiac Events in Patients With Genotype-Confirmed Long-QT Syndrome and Normal-Range Corrected QT Intervals. Journal of the American College of Cardiology, 2011, 57, 51-59.	2.4	297
149	Overexpression of CaMKII β in RyR2R4496C+/ Δ Knock-In Mice Leads to Altered Intracellular Ca ²⁺ Handling and Increased Mortality. Journal of the American College of Cardiology, 2011, 57, 469-479.	2.4	35
150	Risk Factors for Recurrent Syncope and Subsequent Fatal or Near-Fatal Events in Children and Adolescents With Long QT Syndrome. Journal of the American College of Cardiology, 2011, 57, 941-950.	2.4	115
151	Calmodulin kinase II inhibition prevents arrhythmias in RyR2R4496C+/ Δ mice with catecholaminergic polymorphic ventricular tachycardia. Journal of Molecular and Cellular Cardiology, 2011, 50, 214-222.	3.9	113
152	ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). European Heart Journal, 2011, 32, 3147-3197.	2.3	1,793
153	HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace, 2011, 13, 1077-1109.	2.1	749
154	RyRCa ²⁺ Leak Limits Cardiac Ca ²⁺ Window Current Overcoming the Tonic Effect of Calmodulin in Mice. PLoS ONE, 2011, 6, e20863.	2.4	12
155	ST-Segment Elevation in the Setting of a Febrile Illness. , 2011, 16, 303-307.		3
156	Screening for Sudden Cardiac Death in the Young. Circulation, 2011, 123, 1911-1918.	25.2	146
157	Short Communication: Flecainide Exerts an Antiarrhythmic Effect in a Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia by Increasing the Threshold for Triggered Activity. Circulation Research, 2011, 109, 291-295.	12.5	118
158	2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Circulation, 2011, 123, .	25.2	775
159	R Engine Cell: integrating R into the i2b2 software infrastructure. Journal of the American Medical Informatics Association: JAMIA, 2011, 18, 314-317.	3.6	17
160	Barriers to implementation of evidence-based electrical therapies and the need for outcome research: role of European registries. Europace, 2011, 13, ii18-ii20.	2.1	24
161	The European cardiac resynchronization therapy survey: patient selection and implantation practice vary according to centre volume. Europace, 2011, 13, 1445-1453.	2.1	28
162	Y1767C, a novel <i>SCN5A</i> mutation, induces a persistent Na ⁺ current and potentiates ranolazine inhibition of Na _v 1.5 channels. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H288-H299.	3.7	49

#	ARTICLE	IF	PR CITATIONS
163	Genetics of sudden death: focus on inherited channelopathies. <i>European Heart Journal</i> , 2011, 32, 2109-2118.	2.3	113
164	Inherited Dysfunction of Sarcoplasmic Reticulum Ca ²⁺ Handling and Arrhythmogenesis. <i>Circulation Research</i> , 2011, 108, 871-883.	12.5	425
165	When is genetic testing useful in patients suspected to have inherited cardiac arrhythmias?. <i>Current Opinion in Cardiology</i> , 2010, 25, 37-45.	1.7	9
166	Identification of circulating placental mRNA in maternal blood of pregnancies affected with fetal congenital heart diseases at the second trimester of pregnancy: implications for early molecular screening. <i>Prenatal Diagnosis</i> , 2010, 30, 229-234.	2.4	32
167	Trafficking Defects and Gating Abnormalities of a Novel <i>SCN5A</i> Mutation Question Gene-Specific Therapy in Long QT Syndrome Type 3. <i>Circulation Research</i> , 2010, 106, 1374-1383.	12.5	77
168	Purkinje Cells From RyR2 Mutant Mice Are Highly Arrhythmogenic But Responsive to Targeted Therapy. <i>Circulation Research</i> , 2010, 107, 512-519.	12.5	98
169	The Fifteen Years of Discoveries That Shaped Molecular Electrophysiology. <i>Circulation Research</i> , 2010, 107, 451-456.	12.5	36
170	In the RyR2 ^{R4496C} Mouse Model of CPVT, β^2 -Adrenergic Stimulation Induces Ca Waves by Increasing SR Ca Content and Not by Decreasing the Threshold for Ca Waves. <i>Circulation Research</i> , 2010, 107, 1483-1489.	12.5	97
171	Who Are the Long-QT Syndrome Patients Who Receive an Implantable Cardioverter-Defibrillator and What Happens to Them?. <i>Circulation</i> , 2010, 122, 1272-1282.	25.2	287
172	Na ⁺ -dependent SR Ca ²⁺ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation. <i>Cardiovascular Research</i> , 2010, 87, 50-59.	5.7	82
173	Polymorphisms in the NOS1AP Gene Modulate QT Interval Duration and Risk of Arrhythmias in the Long QT Syndrome. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2745-2752.	2.4	169
174	Purkinje cell calcium dysregulation is the cellular mechanism that underlies catecholaminergic polymorphic ventricular tachycardia. <i>Heart Rhythm</i> , 2010, 7, 1122-1128.	2.8	78
175	Magnetic resonance investigations in Brugada syndrome reveal unexpectedly high rate of structural abnormalities. <i>European Heart Journal</i> , 2009, 30, 2241-2248.	2.3	164
176	The European cardiac resynchronization therapy survey. <i>European Heart Journal</i> , 2009, 30, 2450-2460.	2.3	221
177	Routine electrocardiogram and medical history in syncope: a simple approach can identify most high-risk patients. <i>Europace</i> , 2009, 11, 1411-1412.	2.1	4
178	High Efficacy of β^2 -Blockers in Long-QT Syndrome Type 1. <i>Circulation</i> , 2009, 119, 215-221.	25.2	293
179	Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter) in patients with heart failure and increased Ca ²⁺ sensitivity of the Ryanodine Receptor Mutant RyR2 ^{R4496C} Underlies Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Circulation Research</i> , 2009, 104, 201-209.	7.8	119
180	Sensitivity of the Ryanodine Receptor Mutant RyR2 ^{R4496C} Underlies Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Circulation Research</i> , 2009, 104, 201-209.	12.5	140

#	ARTICLE	IF	PR CITATIONS
181	Yield of Genetic Screening in Inherited Cardiac Channelopathies. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2009, 2, 6-15.	7.4	135
182	Charcot-Marie-Tooth type 1a in a child with Long QT syndrome. <i>European Journal of Paediatric Neurology</i> , 2009, 13, 459-462.	1.9	6
183	The genetics of cardiomyopathy: Genotyping and genetic counseling. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2009, 11, 433-446.	0.6	11
184	The Long QT Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia*. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009, 32, .	1.2	8
185	To Replace or Not to Replace: A Systematic Approach to Respond to Device Advisories. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 164-170.	2.1	17
186	Ryanodine receptor and calsequestrin in arrhythmogenesis: What we have learnt from genetic diseases and transgenic mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2009, 46, 149-159.	3.9	62
187	Clinical Implications for Patients With Long QT Syndrome Who Experience a Cardiac Event During Infancy. <i>Journal of the American College of Cardiology</i> , 2009, 54, 832-837.	2.4	89
188	Drugs and Brugada syndrome patients: Review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). <i>Heart Rhythm</i> , 2009, 6, 1335-1341.	2.8	377
189	Sodium channel mutations and arrhythmias. <i>Nature Reviews Cardiology</i> , 2009, 6, 337-348.	37.5	279
190	Catecholaminergic polymorphic ventricular tachycardia: A paradigm to understand mechanisms of arrhythmias associated to impaired Ca ²⁺ regulation. <i>Heart Rhythm</i> , 2009, 6, 1652-1659.	2.8	110
191	IK1 modulates the U-wave: insights in a 100-year-old enigma. <i>Heart Rhythm</i> , 2009, 6, 393-400.	2.8	32
192	Clinical spectrum of patients with a Brugada ECG. <i>Current Opinion in Cardiology</i> , 2009, 24, 74-81.	1.7	53
193	Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Progress in Cardiovascular Diseases</i> , 2008, 51, 23-30.	5.9	167
194	HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations: Developed in partnership with the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA); and in collaboration with the American College of Cardiology (ACC), the American Heart Association (AHA), the European Society of Cardiology (ESC), the Heart Failure Association of ESC (HFA), and the Heart Fail. <i>Europace</i> , 2008, 10, 707-725.	2.1	229
195	Risk of death in the long QT syndrome when a sibling has died. <i>Heart Rhythm</i> , 2008, 5, 831-836.	2.8	66
196	Magnetic resonance imaging in individuals with cardiovascular implantable electronic devices. <i>Europace</i> , 2008, 10, 336-346.	2.1	233
197	Long-QT Syndrome After Age 40. <i>Circulation</i> , 2008, 117, 2192-2201.	25.2	144
198	Luminal Ca ²⁺ Regulation of Single Cardiac Ryanodine Receptors: Insights Provided by Calsequestrin and its Mutants. <i>Journal of General Physiology</i> , 2008, 131, 325-334.	2.4	128

#	ARTICLE	IF	PR CITATIONS
217	Arrhythmogenic Mechanisms in a Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Circulation Research</i> , 2007, 101, 1039-1048.	12.5	269
218	Long QT Syndrome in Adults. <i>Journal of the American College of Cardiology</i> , 2007, 49, 329-337.	2.4	384
219	Long QT Syndrome and Pregnancy. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1092-1098.	2.4	327
220	Cardiovascular risks of atypical antipsychotic drug treatment. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 882-890.	2.0	66
221	Molecular and Electrophysiological Bases of Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Journal of Cardiovascular Electrophysiology</i> , 2007, 18, 791-797.	2.1	115
222	Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). <i>European Heart Journal</i> , 2007, 28, 2803-2817.	2.3	344
223	Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Herz</i> , 2007, 32, 212-217.	0.8	42
224	Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. <i>European Heart Journal</i> , 2006, 27, 1341-1381.	2.3	1,215
225	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. <i>Journal of the American College of Cardiology</i> , 2006, 48, e247-e346.	2.4	1,325
226	Arrhythmogenic Mechanism of Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Journal of Arrhythmia</i> , 2006, 22, 202-208.	1.4	4
227	AB23-1. <i>Heart Rhythm</i> , 2006, 3, S47.	2.8	0
228	Current Strategies to Diminish the Impact of Cardiovascular Diseases in Women. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2006, 59, 1190-1193.	0.5	0
229	Estrategias actuales para reducir el impacto de las enfermedades cardiovasculares en la mujer. <i>Revista Espanola De Cardiologia</i> , 2006, 59, 1190-1193.	1.1	5
230	Brugada syndrome. <i>Orphanet Journal of Rare Diseases</i> , 2006, 1, .	3.2	34
231	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillationâ€”Executive Summary. <i>Journal of the American College of Cardiology</i> , 2006, 48, 854-906.	2.4	1,067
232	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 14 2.1 663	2.1	663
233	Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. <i>Europace</i> , 2006, 8, 651-745. Long QT syndrome and short QT syndrome: how to make correct diagnosis and what about eligibility for sports activity. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 250-256.	1.2	34
234	Computer simulation of wild-type and mutant human cardiac Na ⁺ current. <i>Medical and Biological Engineering and Computing</i> , 2006, 44, 35-44.	2.4	11

#	ARTICLE	IF	PR CITATIONS
235	Gene-specific therapy for inherited arrhythmogenic diseases. , 2006, 110, 1-13.		25
236	ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with) Tj ETQq0 0 0 r gBT /Overlock 10 Tf 5	2.3	465
237	with the European Heart Rhythm Associat. European Heart Journal, 2006, 27, 2099-2140. European Heart Rhythm Association Guidance Document on cardiac rhythm management product performance. Europace, 2006, 8, 313-322.	2.1	20
238	Risk of Aborted Cardiac Arrest or Sudden Cardiac Death During Adolescence in the Long-QT Syndrome. JAMA - Journal of the American Medical Association, 2006, 296, 1249.	17.1	271
239	Improving patient access to novel medical technologies in Europe. European Heart Journal, 2006, 27, 882-885.	2.3	6
240	Cost-effectiveness of neonatal ECG screening for the long QT syndrome. European Heart Journal, 2006, 27, 1824-1832.	2.3	129
241	Female Predominance and Transmission Distortion in the Long-QT Syndrome. New England Journal of Medicine, 2006, 355, 2744-2751.	43.7	82
242	Arrhythmogenesis in Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation Research, 2006, 99, 292-298.	12.5	302
243	Abnormal Interactions of Calsequestrin With the Ryanodine Receptor Calcium Release Channel Complex Linked to Exercise-Induced Sudden Cardiac Death. Circulation Research, 2006, 98, 1151-1158.	12.5	184
244	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation, 2006, 114, .	25.2	1,057
245	Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 876-885.	2.4	151
246	ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias) Tj ETQq0 0 0 r gBT /Overlock 10 Tf 5	2.1	557
247	Rhythm Association and the Heart R. Europace, 2006, 8, 746-837. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillationâ€“executive summary. European Heart Journal, 2006, 27, 1979-2030.	2.3	621
248	Clinical Phenotype and Functional Characterization of CASQ2 Mutations Associated With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2006, 114, 1012-1019.	25.2	196
249	C-terminal HERG (LQT2) mutations disrupt IKr channel regulation through 14-3-3 μ . Human Molecular Genetics, 2006, 15, 2888-2902.	3.0	52
250	Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. European Heart Journal, 2006, 27, 994-1005.	2.3	332
251	Role of Genetic Analyses in Cardiology. Circulation, 2006, 113, 1130-1135.	25.2	89
252	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Circulation, 2006, 114, .	25.2	2,148

#	ARTICLE	IF	PR CITATIONS
253	Psychological Stress Preceding Idiopathic Ventricular Fibrillation. <i>Psychosomatic Medicine</i> , 2005, 67, 359-365.	2.2	49
254	Endocardial Implantation of a Cardioverter Defibrillator in Early Childhood. <i>Journal of Cardiovascular Electrophysiology</i> , 2005, 16, 1381-1383.	2.1	5
255	From Genes to Cell Therapy: Molecular Medicine Meets Clinical EP. <i>Journal of Cardiovascular Electrophysiology</i> , 2005, 16, 552-552.	2.1	5
256	Genetic Testing in the Long QT Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 2975.	17.1	430
257	A Novel Form of Short QT Syndrome (SQT3) Is Caused by a Mutation in the <i>KCNJ2</i> Gene. <i>Circulation Research</i> , 2005, 96, 800-807.	12.5	606
258	Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. <i>European Heart Journal</i> , 2005, 26, 384-416.	2.3	1,127
259	Bidirectional Ventricular Tachycardia and Fibrillation Elicited in a Knock-In Mouse Model Carrier of a Mutation in the Cardiac Ryanodine Receptor. <i>Circulation Research</i> , 2005, 96, .	12.5	257
260	Cardiac Histological Substrate in Patients With Clinical Phenotype of Brugada Syndrome. <i>Circulation</i> , 2005, 112, 3680-3687.	25.2	337
261	Evidence-based vs. 'impressionist'™ medicine: how best to implement guidelinesThe opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> .. <i>European Heart Journal</i> , 2005, 26, 1155-1158.	2.3	36
262	Evidence-based vs. 'impressionist' medicine: how best to implement guidelines: reply. <i>European Heart Journal</i> , 2005, 26, 2474-2475.	2.3	0
263	Gender-specific prescription for cardiovascular diseases?. <i>European Heart Journal</i> , 2005, 26, 1571-1572.	2.3	35
264	Catecholaminergic polymorphic ventricular tachycardia. <i>Heart Rhythm</i> , 2005, 2, 550-554.	2.8	86
265	Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. <i>European Heart Journal</i> , 2005, 26, 516-524.	2.3	1,092
266	Recommendations for competitive sports participation in athletes with cardiovascular disease: A consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the <i>European Society of Cardiology</i> . <i>European Heart Journal</i> , 2005, 26, 1422-1445.	2.3	917
267	Cardiac and skeletal muscle disorders caused by mutations in the intracellular Ca ²⁺ release channels. <i>Journal of Clinical Investigation</i> , 2005, 115, 2033-2038.	10.7	89
268	ESC-ERC recommendations for the use of automated external defibrillators (AEDs) in Europe. <i>European Heart Journal</i> , 2004, 25, 437-445.	2.3	81
269	Left Cardiac Sympathetic Denervation in the Management of High-Risk Patients Affected by the Long-QT Syndrome. <i>Circulation</i> , 2004, 109, 1826-1833.	25.2	643
270	Inherited Arrhythmogenic Diseases. <i>Circulation Research</i> , 2004, 94, 140-145.	12.5	82

#	ARTICLE	IF	PR CITATIONS
271	Expert consensus document on β -adrenergic receptor blockers The Task Force on Beta-Blockers of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 1341-1362.	2.3	490
272	Endocardial Implantation of a Cardioverter-Defibrillator in a 13-Month-Old Child Affected by Long-QT Syndrome and Syndactyly. <i>Circulation</i> , 2004, 110, .	25.2	6
273	Expert Consensus Document on the Use of Antiplatelet Agents The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 166-181.	2.3	340
274	Nav1.5 E1053K mutation causing Brugada syndrome blocks binding to ankyrin-G and expression of Nav1.5 on the surface of cardiomyocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 17533-17538.	7.6	360
275	From trials to guidelines to clinical practice: the need for improvement. <i>Europace</i> , 2004, 6, 176-178.	2.1	3
276	Abnormal Calcium Signaling and Sudden Cardiac Death Associated With Mutation of Calsequestrin. <i>Circulation Research</i> , 2004, 94, 471-477.	12.5	160
277	A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 9137-9142.	7.6	307
278	Genetics of Cardiac Arrhythmias and Sudden Cardiac Death. <i>Annals of the New York Academy of Sciences</i> , 2004, 1015, 96-110.	4.1	81
279	Catecholaminergic Polymorphic Ventricular Tachycardia, Recurrent Syncope, and Implantable Loop Recorder. <i>Journal of Cardiovascular Electrophysiology</i> , 2004, 15, 729-729.	2.1	24
280	Drug-Induced Torsades de Pointes and Implications for Drug Development. <i>Journal of Cardiovascular Electrophysiology</i> , 2004, 15, 475-495.	2.1	325
281	Policy Statement. <i>Resuscitation</i> , 2004, 60, 245-252.	2.8	29
282	Title is missing!. <i>European Heart Journal</i> , 2004, 25, 2243-2278.	2.3	933
283	Documento de Consenso de Expertos sobre el uso de inhibidores de la enzima de conversi3n de la angiotensina en la enfermedad cardiovascular. <i>Revista Espanola De Cardiologia</i> , 2004, 57, 1213-1232.	1.1	8
284	Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome. <i>Heart Rhythm</i> , 2004, 1, 276-283.	2.8	167
285	Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome. <i>Journal of the American College of Cardiology</i> , 2004, 44, 117-125.	2.4	134
286	Title is missing!. <i>European Heart Journal</i> , 2004, 25, 2054-2072.	2.3	363
287	CaV1.2 Calcium Channel Dysfunction Causes a Multisystem Disorder Including Arrhythmia and Autism. <i>Cell</i> , 2004, 119, 19-31.	34.1	1,523
288	Guidelines on Prevention, Diagnosis and Treatment of Infective Endocarditis Executive Summary The Task Force on Infective Endocarditis of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 267-276.	2.3	631

#	ARTICLE	IF	PR CITATIONS
289	Postmortem Molecular Analysis in Victims of Sudden Unexplained Death. American Journal of Forensic Medicine and Pathology, 2004, 25, 182-184.	0.7	50
290	Catecholaminergic Polymorphic Ventricular Tachycardia. Pediatric Emergency Care, 2004, 20, 175-177.	1.0	28
291	Risk Stratification in the Long-QT Syndrome. New England Journal of Medicine, 2003, 348, 1866-1874.	43.7	1,373
292	Title is missing!. Journal of Interventional Cardiac Electrophysiology, 2003, 9, 93-101.	2.1	34
293	A Newly Characterized SCN5A Mutation Underlying Brugada Syndrome Unmasked by Hyperthermia. Journal of Cardiovascular Electrophysiology, 2003, 14, 407-411.	2.1	106
294	Location of Mutation in the KCNQ1 and Phenotypic Presentation of Long QT Syndrome. Journal of Cardiovascular Electrophysiology, 2003, 14, 1149-1153.	2.1	70
295	To the Editor. Journal of Cardiovascular Electrophysiology, 2003, 14, 1131-1133.	2.1	0
296	How Really Rare Are Rare Diseases?:. Journal of Cardiovascular Electrophysiology, 2003, 14, 1120-1121.	2.1	112
297	Flecainide Test in Brugada Syndrome: A Reproducible but Risky Tool. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 338-341.	1.2	94
298	Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. Journal of the American College of Cardiology, 2003, 41, 633-642.	2.4	207
299	Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. Journal of the American College of Cardiology, 2003, 42, 103-109.	2.4	263
300	American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2003, 42, 1687-1713.	2.4	1,488
301	ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias—This document does not cover atrial fibrillation; atrial fibrillation is covered in the ACC/AHA/ESC guidelines on the management of patients with atrial fibrillation found on the ACC, AHA, and ESC Web sites.â€”executive summary. Journal of the American College of Cardiology, 2003, 42, 1493-1531.	2.4	676
302	FKBP12.6 Deficiency and Defective Calcium Release Channel (Ryanodine Receptor) Function Linked to Exercise-Induced Sudden Cardiac Death. Cell, 2003, 113, 829-840.	34.1	720
303	From Vulnerable Plaque to Vulnerable Patient. Circulation, 2003, 108, 1664-1672.	25.2	2,423
304	From Vulnerable Plaque to Vulnerable Patient. Circulation, 2003, 108, 1772-1778.	25.2	1,602
305	ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmiasâ€”Executive Summary. Circulation, 2003, 108, 1871-1909.	25.2	665
306	Cardiac Sodium Channel Diseases. Clinical Chemistry and Laboratory Medicine, 2003, 41, .	2.4	33

#	ARTICLE	IF	PR CITATIONS
307	Update of the guidelines on sudden cardiac death of the European Society of Cardiology. European Heart Journal, 2003, 24, 13-15.	2.3	137
308	Management of Grown Up Congenital Heart Disease. European Heart Journal, 2003, 24, 1035-1084.	2.3	461
309	ACC/AHA/HRS guidelines for the management of patients with supraventricular arrhythmias ^{SC} executive summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With) Tj ETQq1 1 0.784314 fgbT /Overlock 10	2.3	116
310	Medical Practice Guidelines Separating science from economics. European Heart Journal, 2003, 24, 1857-1897.	2.3	32
311	Clinical and Molecular Characterization of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2002, 106, 69-74.	25.2	1,161
312	Increased Risk of Arrhythmic Events in Long-QT Syndrome With Mutations in the Pore Region of the Human Ether-a-go-go-Related Gene Potassium Channel. Circulation, 2002, 105, 794-799.	25.2	381
313	Proposed Diagnostic Criteria for the Brugada Syndrome. Circulation, 2002, 106, 2514-2519.	25.2	804
314	A novel <i>SCN5A</i> mutation associated with long QT-3: altered inactivation kinetics and channel dysfunction. Physiological Genomics, 2002, 10, 191-197.	2.5	68
315	Genetics of ventricular tachycardia. Current Opinion in Cardiology, 2002, 17, 222-228.	1.7	11
316	Differential effects of beta-blockade on dispersion of repolarization in the absence and presence of sympathetic stimulation between the lqt1 and lqt2 forms of congenital long qt syndrome. Journal of the American College of Cardiology, 2002, 39, 1984-1991.	2.4	83
317	Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia. Journal of Cellular Physiology, 2002, 190, 1-6.	4.2	188
318	Programmed Electrical Stimulation in Brugada Syndrome: How Reproducible Are the Results?. Journal of Cardiovascular Electrophysiology, 2002, 13, 880-887.	2.1	52
319	Title is missing!. Cardiovascular Drugs and Therapy, 2002, 16, 19-23.	2.1	3
320	Title is missing!. Cardiovascular Drugs and Therapy, 2002, 16, 89-92.	2.1	24
321	Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. Journal of Clinical Investigation, 2002, 110, 1201-1209.	10.7	187
322	Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. Journal of Clinical Investigation, 2002, 110, 1201-1209.	10.7	115
323	Carbon Monoxide Cardiotoxicity. Journal of Toxicology: Clinical Toxicology, 2001, 39, 35-44.	1.5	107
324	Sympathetic stimulation produces a greater increase in both transmural and spatial dispersion of repolarization in LQT1 than LQT2 forms of congenital long QT syndrome. Journal of the American College of Cardiology, 2001, 37, 911-919.	2.4	117

#	ARTICLE	IF	PR CITATIONS
325	Cardiac Damage in Pediatric Carbon Monoxide Poisoning. <i>Journal of Toxicology: Clinical Toxicology</i> , 2001, 39, 45-51.	1.5	25
326	Molecular diagnosis in a child with sudden infant death syndrome. <i>Lancet, The</i> , 2001, 358, 1342-1343.	52.8	163
327	Electrocardiographic Prediction of Abnormal Genotype in Congenital Long QT Syndrome: Experience in 101 Related Family Members. <i>Journal of Cardiovascular Electrophysiology</i> , 2001, 12, 455-461.	2.1	81
328	Foretelling the Future in Brugada Syndrome: Do We Have the Crystal Ball?. <i>Journal of Cardiovascular Electrophysiology</i> , 2001, 12, 1008-1009.	2.1	16
329	Variable Expression of Long QT Syndrome Among Gene Carriers from Families with Five Different HERG Mutations. <i>Annals of Noninvasive Electrocardiology</i> , 2001, 7, 40-46.	1.2	34
330	Inherited Brugada and Long QT-3 Syndrome Mutations of a Single Residue of the Cardiac Sodium Channel Confer Distinct Channel and Clinical Phenotypes. <i>Journal of Biological Chemistry</i> , 2001, 276, 30623-30630.	2.2	190
331	Inferior Vena Cava Loop of the Implantable Cardioverter Defibrillator Endocardial Lead: A Possible Solution to the Growth Problem in Pediatric Implantation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2000, 23, 2108-2112.	1.2	25
332	Evidence for a Cardiac Ion Channel Mutation Underlying Drug-Induced QT Prolongation and Life-Threatening Arrhythmias. <i>Journal of Cardiovascular Electrophysiology</i> , 2000, 11, 691-696.	2.1	314
333	Long QT and Brugada Syndromes: From Genetics to Clinical Management. <i>Journal of Cardiovascular Electrophysiology</i> , 2000, 11, 1174-1178.	2.1	23
334	Significance of QT dispersion in the long QT syndrome. <i>Progress in Cardiovascular Diseases</i> , 2000, 42, 345-350.	5.9	22
335	Clinical and genetic variables associated with acute arousal and nonarousal-related cardiac events among subjects with the long QT syndrome. <i>American Journal of Cardiology</i> , 2000, 85, 457-461.	1.9	74
336	Mechanisms of K_{s} suppression in LQT1 mutants. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2000, 279, H3003-H3011.	3.7	71
337	Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2000, 279, H1748-H1756.	3.7	91
338	A common polymorphism associated with antibiotic-induced cardiac arrhythmia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 10613-10618.	7.6	477
339	A Molecular Link between the Sudden Infant Death Syndrome and the Long-QT Syndrome. <i>New England Journal of Medicine</i> , 2000, 343, 262-267.	43.7	347
340	Brugada syndrome and sudden cardiac death in children. <i>Lancet, The</i> , 2000, 355, 808-809.	52.8	247
341	Title is missing!. <i>Journal of Interventional Cardiac Electrophysiology</i> , 1999, 3, 198-201.	0.9	7
342	Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. <i>American Journal of Cardiology</i> , 1999, 84, 876-879.	1.9	222

#	ARTICLE	IF	PR CITATIONS
343	Exploring the Hidden Danger of Noncardiac Drugs. <i>Journal of Cardiovascular Electrophysiology</i> , 1998, 9, 1114-1116.	2.1	42
344	The Long QT Syndrome. <i>Annals of Noninvasive Electrocardiology</i> , 1998, 3, 63-73.	1.2	28
345	Influence of the Genotype on the Clinical Course of the Long-QT Syndrome. <i>New England Journal of Medicine</i> , 1998, 339, 960-965.	43.7	760
346	Molecular Biology of the Long QT Syndrome: Impact on Management. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1997, 20, 2052-2057.	1.2	40
347	Title is missing!. <i>Journal of Interventional Cardiac Electrophysiology</i> , 1997, 1, 244-247.	0.9	5
348	Evaluation of the Spatial Aspects of T-Wave Complexity in the Long-QT Syndrome. <i>Circulation</i> , 1997, 96, 3006-3012.	25.2	159
349	Differential Response to Na ⁺ Channel Blockade, β -Adrenergic Stimulation, and Rapid Pacing in a Cellular Model Mimicking the SCN5A and HERG Defects Present in the Long-QT Syndrome. <i>Circulation Research</i> , 1996, 78, 1009-1015.	12.5	155
350	Left Cardiac Sympathetic Denervation in Long QT Syndrome Patients. <i>Journal of Interventional Cardiology</i> , 1995, 8, 776-781.	1.4	12
351	Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. <i>Human Molecular Genetics</i> , 1995, 4, 1603-1607.	3.0	331
352	Sympathetic activation, ventricular repolarization and I _K block: Implications for the antifibrillatory efficacy of potassium channel blocking agents. <i>Journal of the American College of Cardiology</i> , 1995, 25, 1609-1614.	2.4	43
353	<i>SCN5A</i> and <i>HERG</i> Genes Have Differential Responses to Na ⁺	25.2	727
354	Electrophysiologic mechanisms involved in the development of torsades de pointes. <i>Cardiovascular Drugs and Therapy</i> , 1991, 5, 203-212.	2.1	19
355	Delineation of the influence of propionylcarnitine on the accumulation of long-chain acylcarnitines and electrophysiologic derangements evoked by hypoxia in canine myocardium. <i>Cardiovascular Drugs and Therapy</i> , 1991, 5, 67-76.	2.1	3
356	The Importance of β -Adrenergic Stimulation of Cardiac Tissue and its Contribution to Arrhythmogenesis During Ischemia. <i>Journal of Cardiovascular Electrophysiology</i> , 1990, 1, 529-542.	2.1	5
357	Efficacy and safety of flecainide in low-risk patients with chronic ventricular arrhythmias: A two-year follow-up. <i>American Heart Journal</i> , 1989, 117, 1258-1264.	3.0	7
358	Ventricular fibrillation induced by the interaction between acute myocardial ischemia and sympathetic hyperactivity: Effect of nifedipine. <i>American Heart Journal</i> , 1988, 116, 37-43.	3.0	24
359	Antiarrhythmic efficacy of penticainide and comparison with disopyramide, flecainide, propafenone and mexiletine by acute oral drug testing. <i>American Journal of Cardiology</i> , 1987, 60, 1068-1072.	1.9	14
360	Efficacy of diltiazem in two experimental feline models of sudden cardiac death. <i>Journal of the American College of Cardiology</i> , 1986, 8, 661-668.	2.4	29

#	ARTICLE	IF	PR CITATIONS
361	Lack of correlation between occlusion and reperfusion arrhythmias in the cat. American Heart Journal, 1985, 109, 932-936.	3.0	11